Drug Design At The Peroxisome Proliferator-Activated Receptor - Ciantar, Julienne;Shoemake, Claire;Azzopardi, Lilian M.
44,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
22 °P sammeln
  • Broschiertes Buch

The Peroxisome Proliferator-Activated Receptor Gamma (PPAR ) agonist Rosiglitazone, has recently been withdrawn from the European market and its use has been restricted in the US due to its undesirable effects which were considered to outweigh its benefits. This study explores the two agonist bound conformations of the PPAR , as exemplified by its binding to Rosiglitazone and that to Farglitazar. Furthermore, it evaluates whether they should be targeted separately in the context of drug design studies. The binding modalities of Rosiglitazone and Farglitazar were studied in great detail and a…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
The Peroxisome Proliferator-Activated Receptor Gamma (PPAR ) agonist Rosiglitazone, has recently been withdrawn from the European market and its use has been restricted in the US due to its undesirable effects which were considered to outweigh its benefits. This study explores the two agonist bound conformations of the PPAR , as exemplified by its binding to Rosiglitazone and that to Farglitazar. Furthermore, it evaluates whether they should be targeted separately in the context of drug design studies. The binding modalities of Rosiglitazone and Farglitazar were studied in great detail and a series of molecules capable of agonist activity at the PPAR have been designed, with the potential to act as leads in a drug design process.
Autorenporträt
Julienne graduated with a Masters in Pharmacy in 2012. The authors form part of the Department of Pharmacy, Faculty of Medicine and Surgery, University of Malta, which is headed by Professor Lilian Azzopardi. Dr.Claire Shoemake is the co-ordinater of the Medicinal Chemistry Study Group at the Department.